Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11798851 | 0.87 | MAPT (0.41) | PTGS1MAPTPTGS2LMNA | |
| SCHEMBL5998545 | 0.81 | PTGS1 (0.51) | PTGS1PTGS2L3MBTL1LMNATSHR | |
| SCHEMBL11798859 | 0.78 | MEN1 (0.50) | PTGS1MAPTPTGS2L3MBTL1ALDH1A1 | |
| SCHEMBL2029438 | 0.76 | TP53 (0.33) | PTGS1PTGS2L3MBTL1TLR8 | |
| SCHEMBL11273992 | 0.75 | PARP10 (0.30) | — | |
| SCHEMBL11796984 | 0.75 | KDM4E (0.39) | MAPTLMNAALDH1A1HPGD | |
| SCHEMBL12871107 | 0.73 | POLB (0.39) | PTGS1MAPTPTGS2LMNAHTT | |
| SCHEMBL4270430 | 0.73 | MAPT (0.39) | PTGS1MAPTPTGS2L3MBTL1TLR8 | |
| SCHEMBL1285445 | 0.72 | LMNA (0.42) | MAPTLMNAALDH1A1HPGDHTT | |
| SCHEMBL11443302 | 0.72 | MEN1 (0.39) | MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101646657-B | Process for producing trichloropyrimidine compound | SUMITOMO CHEMICAL CO JP | 2012-08-08 | — | — | CN | disclosed |
| US-8158787-B2 | Process for producing trichloropyrimidine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2128141-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160630-A1 | PROCESS FOR PRODUCING TRICHLOROPYRIMIDINE COMPOUND | DPYD, TYMP, TST | PTGS1 1327/4885MAPT 4738/4885PTGS2 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.